Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Eftilagimod Alpha · IMP321

Fusion protein · Immune activation, directed at MHC class II molecules · developed by Immutep S.A.S.

Phase 2/3 Most advanced trial
IMMP Developer
8 Registered trials

What is Eftilagimod Alpha?

Eftilagimod alpha is a soluble recombinant fusion protein derived from the extracellular Ig-like domains of the LAG-3 (CD223) protein. It binds with high affinity to MHC class II molecules on dendritic cells, promoting their maturation, migration to lymph nodes and cross-presentation of antigens to T cells. It is studied in combination with tumor antigens or paclitaxel in breast cancer, non-small cell lung cancer, soft tissue sarcoma and melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
IMP321, efti, LAG-3Ig, eftilagimod alfa, LAG-3Ig fusion protein
Drug type
Fusion protein
Targets
MHC class II molecules
Mechanism
Immune activation, directed at MHC class II molecules
Pathways
dendritic cell maturation and migration, antigen cross-presentation to T cells, cytotoxic T cell responses
Therapy area
Oncology
Developer
Immutep S.A.S. (IMMP)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
SJ82PK3HWA

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06726265 Phase 3 Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Active not recruiting IMMP
NCT05747794 Phase 2/3 Breast Carcinoma Terminated IMMP
NCT07102940 Phase 2 Breast Cancer Not yet recruiting IMMP
NCT06128863 Phase 2 Neoadjuvant Active not recruiting IMMP
NCT02614833 Phase 2 Adenocarcinoma Breast Stage IV Completed IMMP
NCT01308294 Phase 1/2 Melanoma Terminated IMMP
NCT00365937 Phase 1/2 Melanoma Terminated IMMP
NCT00354861 Phase 1 Healthy Completed IMMP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)Breast CancerHER 2 Negative Breast CancerHR Positive/HER-2 Negative Breast CancerImmunotherapyNeoadjuvantRadiation TherapySarcoma,Soft TissueStage 1-3Adenocarcinoma Breast Stage IVBreast CarcinomaHealthyMelanoma

More from Immutep S.A.S.

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the IMMP page.

Follow IMMP, the company behind Eftilagimod Alpha

See IMMP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMMP catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.